Novartis, not to be outdone by respiratory rivals, inks ‘smart inhaler’ deal

Carly Helfand Respiratory drugmakers have been looking to "smart inhaler" technology to give them a leg up on marketing in a crowded field. And Novartis wants a part ...

Drug price increases saw ‘high water mark’ year in 2015: Analysts

Emily Wasserman Price hikes have landed pharma in hot water lately, with lawmakers, the public and presidential hopefuls lashing out at companies over skyrocketing costs. But things ...

Accelerator’s second NYC biotech startup sets out with $17M and some Gates-backed science

Damian Garde Accelerator, among the financiers looking to kick-start a fledgling biotech hub in New York City, launched its second local project in the form of Lodo Therapeutics, a ...

UPDATED: Shire finally gets it done, bagging Baxalta in $32B buyout

John Carroll It took a few months, but Shire has wrapped a $ 32 billion deal to acquire Baxalta, providing CEO Flemming Ornskov with the big merger that he has been promising investors. FierceBiotech ...

Time for J&J to pay up in $124M Risperdal case as SCOTUS deflects final appeal

Tracy Staton Johnson & Johnson fell short Monday in its final effort to escape a Risperdal marketing penalty in South Carolina. The U.S. Supreme Court declined to ...

With FDA nod, Actelion adds blockbuster hopeful Uptravi to PAH portfolio

Carly Helfand Actelion has been laboring to fill the void left by declining sales of aged pulmonary arterial hypertension (PAH) med Tracleer. And now, it has another tool ...

Alzheimer’s player Anavex reveals SEC probe; shares dive

John Carroll Shares of Anavex took a nasty hit after the New York-based biotech issued a 10-K this morning that included news of an SEC probe, evidently focused on "unusual" ...

Celgene opens door for early launch of Revlimid generics

Emily Wasserman Just in time for the holidays, Celgene settled the score with Natco Pharma over patents for its cancer blockbuster Revlimid. The company is allowing the Indian generics ...

Kamada’s rabies treatment clears Phase III with an FDA app on deck

Damian Garde Kamada's immunoglobulin treatment for rabies met its main goal in a late-stage trial, clearing the way for an FDA application next year. FierceBiotech News

Australia bets $1B on pricey hep C drugs in broad effort to eradicate the disease

Carly Helfand Good news for Gilead Sciences and Bristol-Myers Squibb: Australia's federal government wants to eliminate hepatitis C in the country. And it plans to shell out $ ...

With Shkreli out, new Turing boss slashes jobs, hunts for a CEO

John Carroll With former Turing founder and CEO Martin Shkreli facing federal fraud and looting charges, the biotech's new helmsman is cutting costs and hunting for someone who'd ...

With Big Pharma backing, eFFECTOR plots solid tumor trial with $40M round

John Carroll More than two years after landing a hefty launch round, San Diego-based eFFECTOR Therapeutics has scooped up a $ 40 million financing from an expanded group of investors, ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS